Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment

NCT00425204 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00425204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00425204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2004
Completion date
March 31, 2008
Enrollment
31 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma, colorectal cancer, non-small cell lung cancer, prostate cancer, solid tumors